Phase 4Completed
Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM
Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM: A 24-Week, Multicentre, Randomized, Parallel, Interventional, Non-inferiority, Open-label Study
- Sponsor
- AstraZeneca (Industry)
- Enrollment
- 633 enrolled
- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Interventions
- Xigduo (Dapagliflozin and Metformin hydrochloride extended-release) tablets; Dapagliflozin tablets and Metformin HCl extended-release tablets
- Ages
- adults, older adults
- Registry
- NCT06327815
Full record on ClinicalTrials.gov
From the registry
Study D1690L00149 is a 24-week, multicentre, randomized, parallel, interventional, non-inferiority, open-label study designed to compare the FDC Regimen of Dapagliflozin/Metformin XR with the Dapagliflozin co-administered with Metformin XR in glycemic lowering control, satisfaction and adherence in Chinese patients with T2DM.
Primary outcomes
- Change in HbA1c from baseline
History
Last registry update
Primary completion
Registered
Started
Papers citing this trial
- Continuous Glucose Monitoring-Based Metrics with Fixed-Dose Combination Versus Co-administered Dapagliflozin/Metformin in Chinese Patients with Type 2 Diabetes Mellitus
Research Square
- Efficacy and Safety of DAPA/MET Fixed-Dose Combination (FDC) vs. Co-Administration (Co-ADM) in Chinese Patients with T2DM
ADA Scientific Sessions 2026 abstract